Assuming 90% coverage, a program in The Gambia using a 9-valent PCV (PCV9) would prevent approximately 630 hospitalizations, 40 deaths, and 1000 DALYs over the first 5 years of life of a birth cohort. The estimated cost would be $670 per DALY averted in The Gambia.
Full Citation:
Kim, S., Lee, G. and Goldie, S.. 2010. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infectious Diseases. 10(260).
Title of Article: Economic evaluation of pneumococcal conjugate vaccination in The Gambia
Author(s): Kim, S., Lee, G. and Goldie, S.
Publication Year: 2010
Publication Name: BMC Infectious Diseases
Publication Volume: 10(260)
Publication Source URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944347/
DOI (Digital Object Identifier): 10.1186/1471-2334-10-260
Topics: Economics & Return on Investment
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: Gambia
WHO Regions: Africa